Molecular Basis for the Regulation of the H3K4 Methyltransferase Activity of PRDM9  by Wu, Hong et al.
Cell Reports
ReportMolecular Basis for the Regulation
of the H3K4 Methyltransferase Activity of PRDM9
Hong Wu,1 Nikolas Mathioudakis,2,3 Boubou Diagouraga,4 Aiping Dong,1 Ludmila Dombrovski,1 Fre´de´ric Baudat,4
Stephen Cusack,2,3 Bernard de Massy,4,* and Jan Kadlec2,3,*
1Structural Genomics Consortium, University of Toronto, MaRS Center, South Tower, 7th Floor, 101 College Street, Toronto, ON M5G 1L7,
Canada
2European Molecular Biology Laboratory, Grenoble Outstation, 6 rue Jules Horowitz, 38042 Grenoble, France
3Unit for Virus Host-Cell Interactions, University Grenoble Alpes-EMBL-CNRS, 6 rue Jules Horowitz, 38042 Grenoble, France
4Institute of Human Genetics, UPR 1142, CNRS, 141 rue de la Cardonille, 34396 Montpellier, France
*Correspondence: bernard.de-massy@igh.cnrs.fr (B.d.M.), kadlec@embl.fr (J.K.)
http://dx.doi.org/10.1016/j.celrep.2013.08.035
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.SUMMARY
PRDM9, a histone lysine methyltransferase, is a key
determinant of the localization of meiotic recombina-
tion hot spots in humans andmice and the only verte-
brate protein known to be involved in hybrid sterility.
Here, we report the crystal structure of the PRDM9
methyltransferase domain in complex with a histone
H3 peptide dimethylated on lysine 4 (H3K4me2) and
S-adenosylhomocysteine (AdoHcy), which provides
insights into the methyltransferase activity of PRDM
proteins. We show that the genuine substrate of
PRDM9 is histone H3 lysine 4 (H3K4) and that the
enzyme possesses mono-, di-, and trimethylation
activities. We also determined the crystal structure
of PRDM9 in its autoinhibited state, which revealed
a rearrangement of the substrate and cofactor bind-
ing sites by a concerted action of the pre-SET and
post-SET domains, providing important insights
into the regulatory mechanisms of histone lysine
methyltransferase activity.INTRODUCTION
In humans, the PRDM family consists of 17 proteins that play
important roles in a wide range of development processes,
including stem cell identity maintenance or cell differentiation
and their deregulation results in various cancers (Hohenauer
andMoore, 2012). PRDMproteins are characterized by the pres-
ence of an N-terminal PR (PRDI-BF1 and RIZ1 homology)
domain followed bymultiple zinc fingers which confer DNA bind-
ing activity. PRDM2, -3, -8, -9, and -16 were shown to possess
histone methyltransferase activity, whereas some other mem-
bers were suggested to recruit histone-modifying enzymes
(Eom et al., 2009; Hayashi et al., 2005; Hohenauer and Moore,
2012; Pinheiro et al., 2012). PR domains are only distantly related
to the classical SET methyltransferase domains. The key signa-ture motifs of SET domains are poorly conserved in the PRDM
family, and the available crystal structures systematically lack
bound substrate and cofactor. Thus, it remains unclear how
the catalytic mechanism of PRDM proteins relates to that of
SET domains (Hohenauer and Moore, 2012).
PRDM9 is the only member of the family (apart from its
paralog PRDM7 in human) to contain a domain related to
Kru¨ppel-associated box (KRAB) often present in transcription
repressors (Birtle and Ponting, 2006) but has been shown to
catalyze methylation of H3K4me2 to H3K4me3 (Hayashi et al.,
2005), a modification typically enriched at transcription start
sites (Barski et al., 2007). PRDM9 may actually not be involved
in transcription regulation but is a key factor in specifying the
sites of meiotic recombination in mouse and human (Baudat
et al., 2010; Myers et al., 2010; Parvanov et al., 2010). This func-
tion is mediated by the DNA binding specificity of its zinc finger
array, and it has been proposed that PRDM9 binds to specific
sites in the genome of oocytes and spermatocytes, where its
methyltransferase activity leads to a local enrichment of
H3K4me3 and recruits the meiotic recombination machinery
(Grey et al., 2011). Whereas the importance of H3K4me3 cata-
lyzed by Set1 in the activity of meiotic recombination sites was
recently demonstrated in S. cerevisiae (Acquaviva et al., 2013;
Sommermeyer et al., 2013), in mammals, the role of H3K4me3
in this process remains unclear. Furthermore, PRDM9 is
involved in hybrid sterility, a function potentially linked to its
role in recombination (Mihola et al., 2009). Here, we present
crystal structures of its catalytic domain in an autoinhibited state
and in complex with the H3K4me2 substrate peptide, providing
insights into the substrate specificity, catalytic mechanism, and
regulation of PRDM proteins.
RESULTS AND DISCUSSION
Structure of the PRDM9 PR/SET Domain in Complex
with the H3K4me2 and AdoHcy
The structure of the PR/SET domain of mouse PRDM9
(mPRDM9) methyltransferase (residues 198–368) in complex
with histone H3K4me2 peptide and AdoHcy (a methylationCell Reports 5, 13–20, October 17, 2013 ª2013 The Authors 13
Figure 1. Crystal Structures of the Catalytic
Domain of PRDM9
(A) Schematic representation of the domain
structure of mouse PRDM9.
(B) Ribbon diagram of the mPRDM9 PR/SET
domain in complex with H3K4me2 peptide and
AdoHcy. The SET domain (residues 245–358) is
shown in blue, pre-SET domain in green, and
truncated post-SET (post-SET*) in yellow. The
H3K4me2 peptide (in red) binds between strand b8
and helix a2.
(C) Structure of the catalytic domain of hPRDM9 in
its unbound form colored as in (B). Helix a2 is
oriented in the opposite direction blocking the
substrate binding cleft. The structure contains an
additional Zn finger within its post-SET domain.
(D) Details of H3K4me2 peptide recognition by
mPRDM9. Only hydrogen bonds formed by pep-
tide side chains are shown.
(E) The environment of H3K4me2 ε-amino group in
the mPRDM9 catalytic site. Ala332 corresponds to
F/Y switch residue Y305 in SETD7 (Del Rizzo et al.,
2010).
See also Figure S1.reaction product) was determined by X-ray crystallography (Fig-
ure 1). The asymmetric unit contains two mPRDM9 molecules:
one in a ternary complex with the H3 peptide and AdoHcy (Fig-
ure 1B) and one in its unbound form (Figures S1A and S1B).
Overall, the mPRDM9 PR/SET domain topology corresponds
to other SET domains, with the conserved central SET domain
fold (Figures 2A, 2B, and S2) flanked by pre-SET and post-SET
regions. The pre-SET domain spans residues 198–244 and forms
a Zn finger that is connected to the SET domain with a long linker
(residues 222–244). The construct used contains only a short
post-SET region fragment (residues 359–368; referred to as
post-SET*) that is only folded in the presence of AdoHcy and
the peptide (Figure S1B).
Although the two SET domain signature motifs (NHS/CxxPN
and ELxF/YDY; x being any amino acid; Qian and Zhou, 2006)
are not well conserved in the PRDM family, the AdoHcy is bound
by mPRDM9 in a conventional way (Figures 2C and 2D),
indicating that only Asn320 of the NHS/CxxPN motif (320-
NCARDDEEQN in mPRDM9) is necessary for cofactor binding.
Surprisingly, in PRDM3, -8, and -16 that were shown to possess14 Cell Reports 5, 13–20, October 17, 2013 ª2013 The Authorsmethyltransferase activity (Eom et al.,
2009; Hohenauer and Moore, 2012;
Pinheiro et al., 2012), this invariant aspar-
agine is replaced by an arginine or gluta-
mine residue (Figure 2C). These proteins,
thus, do not seem to have the potential of
binding AdoHcy in the way that is highly
conserved among SET-domain-contain-
ing methyltransferases and PRDM9. It
is not clear whether arginine or gluta-
mine residues can functionally substitute
for Asn320. In PRDM4, for which the
methyltransferase activity has not been
reported, we could show that the corre-sponding arginine residue can block the AdoHcy binding site
(Figure 2E).
The H3K4me2 peptide binds to PRDM9 in a cleft between
strand b8 and helix a2 similar to other SET domains (Figures
1D and 1E). Electron density was interpretable for residues 1–
7. In addition to backbone interactions with strand b8 and helix
a2, the peptide also makes several side chain contacts with
PRDM9 that might determine its specific recognition (Figure 1D).
These include a hydrogen bond between Gln5 and the post-SET
Glu360 and Thr3 interaction with backbone carbonyl of Ala287.
Arg2 stacks against Tyr361 and makes a hydrogen bond with
AdoHcy.
Substrate Specificity and the Active Site of PRDM9
PRDM9was proposed to methylate H3K4me2, but not H3K4 nor
H3K4me1 (Hayashi et al., 2005). We analyzed the ability of
mPRDM9 (198–368) to bind unmodified H3K4 and H3K4me2
peptides by isothermal titration calorimetry and could show
that mPRDM9 binds the two peptides with dissociation con-
stants of 102 mM and 43 mM, respectively (Figures S3A and
Figure 2. AdoHcy Binding by PRDM
Proteins
(A) Comparison of the core SET domain of PRDM9
(residues 245–358) with residues 215–336 of
SETD7 (PDB code 1O9S; root-mean-square
deviation of 1.83 A˚ for 98 Ca atoms).
(B) Superposition of the core SET domain of
PRDM9 onto MLL1 residues 3830–3945 (PDB
code 2W5Z; root-mean-square deviation of 1.6 A˚
for 96 Ca atoms).
(C) Sequence alignment of PRDM proteins
covering the two SET domain consensus regions
(in red). Identical residues are in green boxes.
Residues corresponding to PRDM9 Asn320
(AdoHcy binding) and Tyr357 (active site), invariant
in other SET domains, are highlighted by a red
frame.
(D) Details of AdoHcy binding by PRDM9. The
AdoHcy interacts with Asn320, main chain atoms
of the AGLG motif (Gly257, Gly259), Tyr 291 of the
I-SET, and Tyr361 and Leu365 of the post-SET
helix a2.
(E) Arg491 in PRDM4 (PDB code 3DB5) corre-
sponding to PRDM9 Asn320 blocks the AdoHcy
binding site.
See also Figure S2.S3B). Additionally, MALDI-TOF mass spectrometry analysis
revealed that mPRDM9 canmono-, di-, and trimethylate unmod-
ified H3K4 peptide (Figures 3A and 3B). Finally, in a coupled fluo-
rescent methylation assay, both H3K4 and H3K4me2 peptides
were efficiently methylated by mPRDM9 (198–368), whereas
H4K20 peptide was not (Figure 3C). The activity on H3K4 was
lower but still significant, probably reflecting the lower binding
affinity (Figure 3C). Together, these results clearly show that
unmodified H3K4 is a genuine substrate of mPRDM9 and that
mPRDM9 possesses mono-, di-, and trimethylation activities.
To exploremorewidely the substrate specificity of PRDM9, we
tested the activity of mPRDM9 (198–368) on an array of 379Cell Reports 5, 13–20distinct peptides corresponding to
different regions of H2A, H2B, H3, and
H4 with various modifications (Fig-
ure S3C; Table S1). Significant methyl-
transferase activity was detected on
H3 (1–19) peptides, confirming H3K4
(me0, -1, and -2) to be efficient substrates
of PRDM9 (Figure 3D). Arg2 methylation
had no significant effect on the H3K4
methylation within H3 (1–19) peptides
carrying K9me3 modification (Figure 3D).
Surprisingly, PRDM9 can also methylate
H3K9 (me0, -1, and, -2) substrates (Fig-
ure 3D) and potentially H3K36 based on
the signal observed on the H3 (26–45)
peptide (Figure S3C). Although no enrich-
ment for H3K9me3 could be detected at a
mouse meiotic recombination site bound
by PRDM9 (Buard et al., 2009), additional
assays for substrate specificities in vitroand in vivo could certainly be interesting. Other SET domain
methyltransferases, such as Ash1 from D. melanogaster, do
display activities on various substrates which may be regulated
in vivo (Beisel et al., 2002).
H3K4me2 is located in the channel formed by Trp293, Tyr357,
and Tyr361. In the active site, the H3K4me2 ε-amino group
is surrounded by three conserved tyrosine residues: Tyr357,
Tyr276, and Tyr341 (Figure 1E). Invariant tyrosines correspond-
ing to Tyr357 have been proposed to be directly involved in
catalysis (Smith and Denu, 2009). We show that the Y357F
mutation completely abolished the in vitro activity of mPRDM9
(Figures 3E and S3C). Similarly, Y276F and Y341F mutants, October 17, 2013 ª2013 The Authors 15
Figure 3. Substrate Specificity of mPRDM9
(A and B) MALDI-TOF mass spectrometry analysis of the H3K4 peptide methylation by PRDM9 (198–368) is shown. Whereas H3K4 peptide incubated in
the absence of mPRDM9 is not methylated (A), after incubation with mPRDM9 (198–368), single, double, and triple methylation could be detected (B). a.u.,
arbitrary units.
(C) Coupled fluorescent methylation assay. H3K4 and H3K4me2 peptides are efficiently methylated bymPRDM9. Nomethylation is observed for H4K20 peptide.
(D) mPRDM9methyltransferase activity on histone H3 peptides. Top panel showsmethylation of H3 (1–19) peptide. Middle panel showsmethylation of H3 (1–19)
R8me2s/K9me3 peptides with various levels of K4 methylation and of K4me1/R8me2s/K9me3 peptide with indicated R2modifications. The bottom panel shows
R2me2s/R8me2s/K4me3 peptides with various levels of K9 methylation. No methylation is detected on H3 (1–19) K4me3/K9me3 peptides.
(E) Mutagenesis of key catalytic residues. Y357F, Y276F, and Y341F mutations abolish the methyltransferase activity of mPRDM9 (198–368).
(F) hPRDM9 (195–415) can methylate the H3K4 peptide. Themethylation activity is4.4 times lower than for hPRDM9 (198–368). Mutations of Asp199 of the pre-
SET domain and Lys374 of the post-SET domain, disrupting the pre-SET/post-SET-inhibitory interaction result in a higher methyltransferase activity (1.6 times
higher for D199Y and 2.4 times higher for D199Y, K374D). The methyltransferase activity was calculated using linear portion of the curves between minute 7 and
15. Gel filtration and thermal shift measurement of melting temperature confirmed the structural integrity of these mutants (data not shown).
See also Figure S3.
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Figure 4. Conformational Changes of the
PRDM9 Active Site
(A) Superposition of mPRDM9 (198–368) and
hPRDM9 (195–415) structures. The post-SET
domains are highlighted in yellow and brown,
respectively. Proposed hinge regions are shown.
(B) Details of the interaction between the pre-SET
and post-SET domain of hPRDM9. Gly370 forms a
hydrogen bond with Asp199. The side chain of
Lys374, which is surrounded by Tyr202, Phe211,
and Trp373, binds to backbone carbonyl of
Asp199. Lys375 makes a salt bridge with Glu196.
(C) Glu360 and Tyr361 participate in the substrate
and cofactor binding in mPRDM9. Coloring cor-
responds to Figure 1B.
(D) Glu360 stabilizes the autoinhibitory conforma-
tion of hPRDM9 by a salt bridge with Arg342, and
Tyr361 blocks the substrate binding cleft. The
catalytic Tyr357 is also displaced.
See also Figure S4.were inactive in methylation assay using the H3K4 peptide (Fig-
ure 3E). Surprisingly, Tyr276 was previously reported to be
dispensable for methyltransferase activity on H3 (Hayashi
et al., 2005). The integrity of the mutated proteins was verified
by gel filtration and thermal shift measurement of melting tem-
perature (Y276F decreased thermal stability of PRDM9 by 5C;
data not shown). Interestingly, Tyr357 is not conserved in
PRDM3 and PRDM16 (Figure 2C). Thus, these PRDM proteins
are either not truly activemethyltransferases or they use different
catalytic residues than those conserved in PRDM9 and all other
SET domains. Tyr341 helps coordinate a water molecule in the
active site (Figure 1E). In our structure, one of the methyl groups
of the H3K4me2 would clash with the modeled position of the S-
adenosyl methionine (AdoMet) donor methyl. Thus, we interpret
our structure as being in a product conformation. Before the final
methylation reaction, the lysine would need to be rotated within
the catalytic site, possibly to position the clashing methyl group
into that occupied by the active site water, as suggested for
SETD7 (Del Rizzo et al., 2010). In zebrafish, both Tyr276 and
Tyr341 are substituted with phenylalanine (Figure S4A), possibly
indicating altered catalytic activity. Gly278 was suggested to be
a key residue for the activity of mPRDM9 (Hayashi et al., 2005).
The structure reveals that Gly278 is located just upstream of
strand b7 forming a b sheet with b8 and b9 and is not in proximity
to the substrate or cofactor binding site (11 A˚ from the H3K4me2Cell Reports 5, 13–20ε-amino group). Thus, this residue is
unlikely to have a direct effect on catalysis
but appears to be important for structural
integrity of the domain because a G278A
mutant cannot be expressed in soluble
form in bacteria (data not shown).
Structure of the Autoinhibited
PRDM9 PR/SET Domain
The post-SET domain is disordered in the
unbound mPRDM9 molecule in the crys-
tal (Figure S1B). Similarly, the post-SETdomains of DIM-5 or MLL1 become fully folded only in the pres-
ence of the AdoHcy/AdoMet cofactor and substrate (Southall
et al., 2009; Zhang et al., 2002). To better understand the role
of the post-SET domain, we produced crystals of a larger frag-
ment of mouse PRDM9 that, however, only diffracted to a low
resolution. We were, however, able to solve the structure of
human PRDM9 fragment spanning residues 195–415 (hPRDM9;
90% sequence identity with mPRDM9; Figure 1C). Compared to
mPRDM9 (198–368), this fragment includes a slightly longer pre-
SET region and an extended post-SET domain including a Zn
finger, which the structure shows loosely associates with the
SET domain via Glu326 and Arg345. Despite the presence of
the substrate peptide and AdoHcy in the crystallization solution,
hPRDM9 (195–415) crystallized in an unbound form. Unexpect-
edly, the hPRDM9 structure reveals that, in the absence of the
substrate and cofactor, the post-SET region is ordered but
undergoes a conformational change and binds across the SET
domain, blocking the peptide binding cleft (Figure 4A). Conse-
quently, also the AdoHcy binding site becomes incomplete sug-
gesting that this is an autoinhibitory conformation. This position
of the post-SET domain is stabilized by several interactions with
the pre-SET domain Zn finger (Figures 4A and 4B). The last res-
idue in the same position between the two structures is Val355.
The following residues that form helix a2 (residues 359–364) in
the ligand bound structure are rotated by 180 around Val355, October 17, 2013 ª2013 The Authors 17
(Figure 4A). The new helix a2 is then formed by residues 362–367
packing against strands b8 and b11. Glu360 and Trp356 make
backbone hydrogen bonds with Leu332 and Gln334 of b11.
Glu360, which is involved in the substrate recognition in the com-
plex structure, makes a salt bridge interaction with Arg342,
whereas Tyr361 that forms the substrate lysine binding channel
in the complex blocks the peptide binding cleft forming a
hydrogen bond with Leu294 (Figures 4C and 4D). The following
helix a3 packs against the pre-SET domain as shown in Fig-
ure 4B. We tested whether hPRDM9 (195–415) maintains meth-
yltransferase activity and find that it is reduced from that of
hPRDM9 (198–368) but still significant (Figure 3F). Thus, it seems
that the presence of AdoMet and the peptide substrate is suffi-
cient to overcome the inhibition and trigger hPRDM9methylation
activity. Additionally, we could show that mutations predicted to
disrupt the inhibitory interaction between the pre-SET and post-
SET domains (D199Y and K374D) increased the activity of
hPRDM9 (195–415; Figure 3F). We propose that PRDM9 resi-
dues 355–356 and the linker between helix a3 and the post-
SET Zn finger function as hinge regions that enable translocation
of the helix a2 between the active conformation where Glu360
and Tyr361 participate in substrate lysine and cofactor binding
and an inhibitory conformation stabilized by Glu360, where
Tyr361 blocks the substrate binding site (Figure 4A). It remains
to be established whether the transition between the stable
rather than disordered conformation of the post-SET domain
and its active state is regulated by other factors or posttransla-
tional modifications during meiosis. This is a unique example
of a complete rearrangement of the substrate and cofactor bind-
ing sites of a histone lysine methyltransferase by a concerted
action of the pre-SET and post-SET domains.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization
A His-tag fusion of mouse PRDM9 (residues 198–368) was expressed in E. coli
BL21Star (DE3) from pProEXHTb vector. The protein was first purified by affin-
ity chromatography using Ni2+ resin. After His-tag cleavage with tobacco etch
virus (TEV) protease, the protein was further purified by a second Ni2+ column
and size-exclusion chromatography. Pure PRDM9 was concentrated with
2 mM AdoHCy and 2 mM H3K4me2 peptide (ARTKme2QTARK-Y; Y added
to facilitate quantification) to 9 mg/ml in a buffer containing 20 mM Tris, pH
7.0, 150mMNaCl, and 5mM b-mercaptoethanol. The best-diffracting crystals
grew within 3 days at 5C in a solution containing 0.2 M ammonium sulfate;
0.1 M Bis-Tris, pH 5.5; and 25% w/v polyethylene glycol (PEG) 3350. For
data collection at 100 K, crystals were snap frozen in liquid nitrogen with a
solution containing mother liquor and 30% (v/v) glycerol.
hPRDM9 (residues 195–415) was expressed as a His-tag fusion in E. coli
BL21 (DE3) V2R-pRARE from pET28-MHL vector. Harvested cells were resus-
pended in phosphate-buffered saline, supplemented with 250mMNaCl, 5mM
imidazole, 3 mM b-mercaptoethanol, 5% glycerol, 0.1% 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate, and 1 mM phenylmethanesul-
fonylfluoride. After affinity purification on 5 ml HiTrap Chelating column (GE
Healthcare), the protein was further purified by size-exclusion chromatog-
raphy. After TEV protease cleavage, hPRDM9 was purified to homogeneity
by ion-exchange chromatography on Source 30Q column (10 3 10) (GE
Healthcare). Pure hPRDM9 protein (8 mg/ml) was crystallized in a solution
containing 23% PEG 3350; 0.2 M ammonium acetate; and 0.1 M BisTris,
pH 5.5. The crystal was frozen in liquid nitrogen using 15% ethylene glycol
as cryoprotectant.
hPRDM4 (residues 390–540) was expressed as a His-tag fusion in E. coli
BL21 (DE3) Codon Plus RIL (Stratagene) from pET28a-LIC vector. The overex-18 Cell Reports 5, 13–20, October 17, 2013 ª2013 The Authorspressed protein was purified as described above for hPRDM9. Purified
PRDM4 (10 mg/ml) was crystallized using hanging drop vapor diffusion
method at 20C by mixing 1.5 ml of the protein solution with 1.5 ml of the reser-
voir solution containing 23% PEG 3350; 0.2 M ammonium acetate; and 0.1 M
BisTris, pH 6.5. The crystal was frozen in liquid nitrogen using Paratone-N as
cryoprotectant.
Data Collection and Structure Determination
Crystals of mPRDM9 (198–368) belong to the space group P212121 with unit
cell dimensions a = 55.7 A˚, b = 78.2 A˚, and c = 107.6 A˚. The asymmetric unit
contains two PRDM9molecules and has a solvent content of 60%. A complete
native data set was collected to a resolution of 2.3 A˚ on beamline ID29 at the
European Synchrotron Radiation Facility (ESRF). The data were processed
using XDS (Kabsch, 2010). The structure was solved by molecular replace-
ment with PHASER (McCoy et al., 2005) using the structure of PRDM11 (Pro-
tein Data Bank [PDB] code 3RAY; 44% sequence identity) as a search model.
Using prime-and-switch density modification of program RESOLVE (Terwil-
liger, 2000) enabled to us to obtain a clearly interpretable map. The structure
was built in COOT (Emsley and Cowtan, 2004) and refined in REFMAC5 (Mur-
shudov et al., 1997) to final R factor of 20.8% andRfree of 24.5% (Table S2) with
all residues in allowed (97% in favored) regions of the Ramachandran plot, as
analyzed by MOLPROBITY (Davis et al., 2004).
X-ray diffraction data for hPRDM9 was collected at 100 K at beamline 19-ID
of Advanced Photon Source at Argonne National Laboratory. Crystals of
hPRDM9 (195–415) belong to the space group P21 with unit cell dimensions
of a = 54.7 A˚, b = 48.8 A˚, c = 78.7 A˚, and b = 100. Data were processed using
HKL-3000 suite (Otwinowski and Minor, 1997). The structure of hPRDM9 was
determined by single-wavelength anomalous dispersion (SAD) phasing
method using a SeMet-substituted crystal. SOLVE/RESOLVE (Terwilliger
and Berendzen, 1999) were used for heavy atom site search, phase improve-
ment, and initial model building. Program BUCCANEER (Cowtan, 2006) and
ARP/wARP (Perrakis et al., 1999) were used for automatic model building.
COOT (Emsley and Cowtan, 2004) was used for model building and visualiza-
tion. Structure was refined with REFMAC5 (Murshudov et al., 1997) to final R
factor of 19.6% and Rfree of 26.4%with all residues in allowed (96% in favored)
regions of the Ramachandran plot, as analyzed by MOLPROBITY (Davis et al.,
2004). Crystal diffraction data and refinement statistics for the structure are
displayed in Table S2. Representative parts of the 2Fo–Fc electron density
maps calculated using the refined models are shown in Figures S4B and S4C.
X-ray diffraction data for hPRDM4 were collected at 100 K on RIGAKU FR-E
DW. Crystals of hPRDM4 belong to the space group I422 with unit cell dimen-
sions of a = 107.3 A˚, b = 107.3 A˚, and c = 133.6 A˚. Data were processed using
HKL-2000 suite (Otwinowski and Minor, 1997). The structure of hPRDM4 was
determined by SAD phasing method using a SeMet-substituted crystal. The
structure was solved by using SHELXD (Sheldrick, 2008). COOT (Emsley
and Cowtan, 2004) was used for model building and visualization. Structure
was refined with REFMAC5 (Murshudov et al., 1997) to final R factor of
22.2% and Rfree of 29.8% with all residues in allowed (92.1% in favored)
regions of the Ramachandran plot, as analyzed by MOLPROBITY (Davis
et al., 2004). Crystal diffraction data and refinement statistics for the structure
are displayed in Table S2.
Methyltransferase Assays
Methyltransferase activity of PRDM9was analyzed using a continuous, fluores-
cent-coupled assay SAMfluoro (G-Bioscience). The AdoHcy product of the
methylation reaction is further converted by a supplied mixture of three
enzymes to hydrogen peroxide that reacts with 10-acetyl-3,7-dihydroxyphe-
noxazine to produce a fluorescent compound Resorufin. The production of
Resorufin was monitored for 30 min at room temperature using an Infinite 200
PRO plate reader (Tecan). The methylation reactions, containing 0.26 or
0.3mMenzymeand0.22mMpeptide substrate,wereset upaccording tomanu-
facturer instructions. The tested substrate includes H3K4 (ARTKQTARK-Y),
H3K4me2 (ARTKme2QTARK-Y), and H4K20 (Y-GKGGKGLGKGGAKRHR
KVLRD) peptides. All peptides include an extra tyrosine residue for quantifica-
tion. All the reactions were performed at least in duplicates, and the differences
between methylation rates calculated from the linear parts of corresponding
curves (above background level) were within 10%.
For mass spectrometry analysis, 1 mM H3K4 peptide was incubated with
5 mM AdoMet in the presence or absence of 10 mM mPRDM9 (198–368) at
room temperature for 2 hr in 20 mM Tris 7.0 and 150 mM NaCl. The reaction
mixture was analyzed by MALDI-TOF mass spectrometry. The duplicate
experiment yielded essentially identical results.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were performed at 25C,
using an ITC200 microcalorimeter (MicroCal). Experiments included 26 injec-
tions of 1.5 ml of 2.7 mM peptide solution into the sample cell containing 60 mM
of mPRDM9 (198–368) in 20 mM Tris 7.0, 150 mM NaCl, and 5 mM b-mercap-
toethanol. The initial data point was deleted, and the last point after saturation
was subtracted from the data sets. Binding isotherms were fitted with a one-
site binding model by nonlinear regression using Origin Software version 7.0
(MicroCal).
Methyltransferase Activity Assay on Peptide Array
Modified histone peptide arrays (Active Motif, catalog number 13005) were
preincubated in methylation buffer (50 mM Tris-HCl, pH 9.0; 100 mM
NaCl; 5 mM dithiothreitol; 10 mM ZnCl2) for 20 min, followed by incubation
with methylation buffer containing 0.58 mM of (methyl-3H)-S-adenosyl-L-
methionine (Perkin Elmer) and 0.2 mM of either wild-type or Y357F mutant
mPRDM9 (198–368) for 10, 30, or 60 min at ambient temperature. The
arrays were washed four times for 5 min with washing buffer (50 mM
NH4HCO3 and 0.1% SDS) and then dried and rinsed with Amplify
NAMP100 solution (GE Healthcare). The arrays were completely dried and
exposed to the Carestream Kodak Biomax MR films in darkness at 80C
for 1–3 days.
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